Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
暂无分享,去创建一个
D. Neuberg | S. Harrison | D. Wesemann | Pei Tong | W. P. Duprex | T. Zuo | Yongfei Cai | Bing Chen | G. Bajic | A. Schmidt | J. Feldman | B. Hauser | M. Seaman | M. Travers | S. Habibi | Yuezhou Chen | Felipe J. N. Lelis | C. Lavine | I. Windsor | Adam Zuiani | Noah B. Whiteman | Avneesh Gautam | L. Rennick | K. R. McCarthy | E. MacDonald | Nicholas Garcia | Lindsay G. A. McKay | Jun Lin | Anthony Griffths | A. Schmidt | W. Duprex
[1] D. Neuberg,et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike , 2021, Cell.
[2] D. Stuart,et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain , 2021, Cell.
[3] A. Iafrate,et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.
[4] M. Malim,et al. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike , 2021, bioRxiv.
[5] A. Sigal,et al. Sixteen novel lineages of SARS-CoV-2 in South Africa , 2021, Nature Medicine.
[6] D. Ho,et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, Research square.
[7] Vineet D. Menachery,et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera , 2021, bioRxiv.
[8] D. Ho,et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, bioRxiv.
[9] M. Nussenzweig,et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, bioRxiv.
[10] P. Dormitzer,et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.
[11] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[12] D. Stuart,et al. The Antigenic Anatomy of SARS-CoV-2 Receptor Binding Domain , 2020, SSRN Electronic Journal.
[13] M. Nussenzweig,et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo , 2020, The Journal of experimental medicine.
[14] W. P. Duprex,et al. Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape , 2020, bioRxiv.
[15] M. Nussenzweig,et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.
[16] I. Wilson,et al. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies , 2020, Biochemical and Biophysical Research Communications.
[17] G. Atwal,et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters , 2020, Science.
[18] D. Burton,et al. Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection , 2020, bioRxiv.
[19] M. Beltramello,et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.
[20] Steven H Kleinstein,et al. Human germinal centres engage memory and naïve B cells after influenza vaccination , 2020, Nature.
[21] D. Burton,et al. Structural basis of a shared antibody response to SARS-CoV-2 , 2020, Science.
[22] Howard Y. Chang,et al. Human B cell clonal expansion and convergent antibody responses to SARS CoV-2 , 2020, bioRxiv.
[23] Qiang Zhou,et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.
[24] J. Sodroski,et al. Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike , 2020, bioRxiv.
[25] J. Dye,et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.
[26] R. Welsh,et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.
[27] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[28] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[29] W. Xu,et al. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin , 2020, Signal Transduction and Targeted Therapy.
[30] L. Gieselmann,et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients , 2020, Cell.
[31] D. Lauffenburger,et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production , 2020, Cell.
[32] L. Stamatatos,et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation , 2020, Immunity.
[33] Ilya J. Finkelstein,et al. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.
[34] M. Nussenzweig,et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.
[35] Marc C. Johnson,et al. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein , 2020, Journal of Virology.
[36] Linqi Zhang,et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.
[37] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[38] Christopher Earl,et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.
[39] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[40] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[41] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[42] S. Pierce,et al. B cell memory: building two walls of protection against pathogens , 2019, Nature Reviews Immunology.
[43] I. Wilson,et al. VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. , 2019, Current opinion in virology.
[44] Spyros Darmanis,et al. High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes , 2018, Science.
[45] D. Burton,et al. Commonality despite exceptional diversity in the baseline human antibody repertoire , 2018, Nature.
[46] C. Rice,et al. A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. , 2018, Cell reports.
[47] Thorsten Wagner,et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM , 2019, Communications Biology.
[48] C. Rice,et al. Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico , 2017, Cell.
[49] D. Agard,et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy , 2017, Nature Methods.
[50] N. Grigorieff,et al. CTFFIND4: Fast and accurate defocus estimation from electron micrographs , 2015, bioRxiv.
[51] T. Kepler,et al. Viral Receptor-Binding Site Antibodies with Diverse Germline Origins , 2015, Cell.
[52] Sjors H.W. Scheres,et al. RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.
[53] J. Yewdell,et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of Experimental Medicine.
[54] Jaap Goudsmit,et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.
[55] David N Mastronarde,et al. Automated electron microscope tomography using robust prediction of specimen movements. , 2005, Journal of structural biology.
[56] John L. Sullivan,et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.
[57] D. Calado,et al. Germinal Centers , 2017, Methods in Molecular Biology.
[58] Michel C Nussenzweig,et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.